Peptides for inducing Chagas disease responses
The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.
1. A method of inducing an immune response in a subject comprising administering to a subject one or more peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-5 and 7-30, wherein (a) at least one trans-sialidase peptide and one non-trans-sialidase peptide are administered; (b) at least one functional trans-sialidase peptide and at least one non-functional trans-sialidase peptide are administered; (c) at least one functional trans-sialidase peptide and at least one non-trans-sialidase peptide are administered; or (d) at least one non-functional trans-sialidase peptide and at least one non-trans-sialidase peptide are administered.
2. The method of claim 1 , wherein said peptide or peptides is/are 9-15 residues in length.
3. The method of claim 1 , wherein said peptide or peptides is/are fused to another amino acid sequence.
4. The method of claim 1 , wherein at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 distinct peptides are administered to said subject.
5. The method of claim 1 , further comprising inducing an immune response to a peptide comprising SEQ ID NO: 6.
6. The method of claim 1 , wherein said non-trans-sialidase protein is selected from the group consisting of cruzipain precursor, surface protease GP63, histone H3, ATP synthase, citrate synthase, pitrilysin-like metalloprotease, retrotransposon host spot protein, HSP70, surafe protein ToIT, dynein light chain, pumilio /PUR RNA binding protein, and mucin-asociated surface protein.
7. The method of claim 1 , further comprising multiple administrations.
8. The method of claim 1 , wherein administration comprises injection.
9. The method of claim 1 , wherein said peptide or peptides is/are administered with an adjuvant.
10. The method of claim 1 , wherein the total amount of peptide administered is between 50 μg/kg and 1 mg/kg.
11. The method of claim 1 , wherein said subject is a human subject.
12. The method of claim 1 , wherein said subject is a non-human subject, such as a mouse.
13. The method of claim 1 , further comprising measuring a CD8 + T cell response in said subject following administration.
14. The method of claim 8 , wherein the injection is subcutaneous, intradermal or intramuscular injection.
15. The method of claim 9 , wherein adjuvant is a squalene adjuvant, a cytokine adjuvant, a lipid adjuvant or a TLR ligand.
16. The method of claim 12 , wherein the non-human subject is a mouse.